Literature DB >> 25589500

Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon.

Michael K Fink1, Ulrich R Kleeberg2, Stefan Bartels3.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25589500      PMCID： PMC4294609          DOI： 10.1634/theoncologist.2014-0273

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  7 in total

1.  Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy.

Authors:  J Y Pierga; B Asselain; M Jouve; V Diéras; M Carton; V Laurence; V Girre; P Beuzeboc; T Palangié; T Dorval; P Pouillart
Journal:  Cancer       Date:  2001-03-15       Impact factor: 6.860

2.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

3.  Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Authors:  Andreas Andreou; Scott Kopetz; Dipen M Maru; Su S Chen; Giuseppe Zimmitti; Antoine Brouquet; Junichi Shindoh; Steven A Curley; Christopher Garrett; Michael J Overman; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

Review 4.  Adjuvant therapy reduces the benefit of palliative treatment in disseminated breast cancer - own findings and review of the literature.

Authors:  Ulrich R Kleeberg; Michael Fink; Hans-Werner Tessen; Alice Nennecke; Stefan Hentschel; Stefan Bartels
Journal:  Onkologie       Date:  2013-05-21

5.  Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

Authors:  Michael J O'Connell; Megan E Campbell; Richard M Goldberg; Axel Grothey; Jean-François Seitz; Jacqueline K Benedetti; Thierry André; Daniel G Haller; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

6.  Is breast cancer survival improving?

Authors:  Sharon H Giordano; Aman U Buzdar; Terry L Smith; Shu-Wan Kau; Ying Yang; Gabriel N Hortobagyi
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

7.  A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.

Authors:  Andrew D Seidman; Stephen Chan; Jin Wang; Chao Zhu; Cong Xu; Binghe Xu
Journal:  Oncologist       Date:  2014-04-04
  7 in total
  5 in total

1.  Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter.

Authors:  Michael K Fink; Ulrich R Kleeberg; Stefan Bartels
Journal:  Oncologist       Date:  2015-06-11

2.  In reply.

Authors:  Binghe Xu; Andrew Seidman; Stephen Chan
Journal:  Oncologist       Date:  2015-01

3.  Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the "ATRESS" phenomenon.

Authors:  Patriek Jurrius; Thomas Green; Hans Garmo; Matthew Young; Massimiliano Cariati; Cheryl Gillett; Anca Mera; Mark Harries; Anita Grigoriadis; Sarah Pinder; Lars Holmberg; Arnie Purushotham
Journal:  Breast       Date:  2020-01-14       Impact factor: 4.380

4.  Does adjuvant therapy reduce postmetastatic survival?

Authors:  M K Fink
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

5.  De novo and recurrent metastatic breast cancer - A systematic review of population-level changes in survival since 1995.

Authors:  S J Lord; K Bahlmann; D L O'Connell; B E Kiely; B Daniels; S A Pearson; J Beith; M K Bulsara; N Houssami
Journal:  EClinicalMedicine       Date:  2022-01-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.